BRPI1012759A2 - anticorpos biespecíficos que se ligam as proteínas do complemento. - Google Patents
anticorpos biespecíficos que se ligam as proteínas do complemento.Info
- Publication number
- BRPI1012759A2 BRPI1012759A2 BRPI1012759A BRPI1012759A BRPI1012759A2 BR PI1012759 A2 BRPI1012759 A2 BR PI1012759A2 BR PI1012759 A BRPI1012759 A BR PI1012759A BR PI1012759 A BRPI1012759 A BR PI1012759A BR PI1012759 A2 BRPI1012759 A2 BR PI1012759A2
- Authority
- BR
- Brazil
- Prior art keywords
- bispecific antibodies
- bind
- proteins
- complement
- complement proteins
- Prior art date
Links
- 108010069112 Complement System Proteins Proteins 0.000 title abstract 2
- 102000000989 Complement System Proteins Human genes 0.000 title abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 101150009981 C5AR1 gene Proteins 0.000 abstract 1
- 101800001654 C5a anaphylatoxin Proteins 0.000 abstract 1
- 102100031506 Complement C5 Human genes 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000004969 inflammatory cell Anatomy 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
anticorpos biespecíficos que se ligam as proteínas do complemento a presente descrição se refere aos anticorpos biespecíficos que podem se ligar a dois ou mais diferentes epítopos. por exemplo, os anticorpos biespecíficos descritos aqui podem se ligar a duas ou mais diferentes proteínas, em que pelo menos duas das proteínas são selecionadas a partir de c5a, c5b, um receptor celular para c5a (por exemplo, c5ar1 ou c5l2), o complexo c5b-9, e um componente ou intermediário de complemento terminal, tal como, c5b-6, c5b-7, ou c5b-8. os anticorpos biespecíficos descritos aqui são úteis para, por exemplo, a inibição do complemento terminal (por exemplo, a montagem e/ ou atividade do complexo c5b-9) e/ ou inflamação mediada pela anafilatoxina c5a (por exemplo, quimio- taxia mediada pela c5a das células inflamatórias imunes). por conseguinte, os anticorpos biespecíficos podem ser empregados nos métodos para o tratamento de uma variedade de distúrbios associados a via do complemento.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21964409P | 2009-06-23 | 2009-06-23 | |
| US22800109P | 2009-07-23 | 2009-07-23 | |
| PCT/US2010/039448 WO2010151526A1 (en) | 2009-06-23 | 2010-06-22 | Bispecific antibodies that bind to complement proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012759A2 true BRPI1012759A2 (pt) | 2019-07-02 |
Family
ID=43386850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012759A BRPI1012759A2 (pt) | 2009-06-23 | 2010-06-22 | anticorpos biespecíficos que se ligam as proteínas do complemento. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110002931A1 (pt) |
| EP (1) | EP2445937B1 (pt) |
| JP (1) | JP2012531418A (pt) |
| KR (1) | KR20120105405A (pt) |
| CN (1) | CN102597005A (pt) |
| AU (1) | AU2010264520A1 (pt) |
| BR (1) | BRPI1012759A2 (pt) |
| CA (1) | CA2766565A1 (pt) |
| IL (1) | IL217087A0 (pt) |
| IN (1) | IN2012DN00424A (pt) |
| MX (1) | MX2011013748A (pt) |
| NZ (1) | NZ597259A (pt) |
| RU (1) | RU2012102021A (pt) |
| WO (1) | WO2010151526A1 (pt) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CN106390117A (zh) * | 2009-10-16 | 2017-02-15 | 奥默罗斯公司 | 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法 |
| BR112012022214A2 (pt) * | 2010-03-01 | 2017-07-04 | Alexion Pharma Inc | métodos e composições para tratar doença de degos |
| BR112013013354A2 (pt) | 2010-11-30 | 2020-10-06 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR101870915B1 (ko) | 2011-04-08 | 2018-06-25 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| US20140255405A1 (en) * | 2011-05-27 | 2014-09-11 | Dutalys | Removal of Monomeric Targets |
| JP6618682B2 (ja) | 2011-06-22 | 2019-12-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 補体阻害剤による慢性障害の治療方法 |
| KR102339315B1 (ko) * | 2012-06-18 | 2021-12-15 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| EP3722320A3 (en) * | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| GB2509260B (en) | 2012-11-02 | 2016-05-04 | True North Therapeutics Inc | Anti-complement C1s antibodies and uses thereof |
| KR102605775B1 (ko) | 2013-03-14 | 2023-11-29 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법 |
| ES2768648T3 (es) | 2013-03-29 | 2020-06-23 | Alexion Pharma Inc | Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento |
| AU2014306002B2 (en) * | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| TWI617580B (zh) | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| WO2016117346A1 (en) * | 2015-01-22 | 2016-07-28 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
| HK1259251A1 (zh) | 2015-04-06 | 2019-11-29 | Bioverativ Usa Inc. | 人源化抗c1s抗体及其使用方法 |
| AU2016282782A1 (en) * | 2015-06-26 | 2018-01-18 | Bioverativ Usa Inc. | Methods of treating autoimmune and alloimmune disorders |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| WO2017205101A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| MY196006A (en) | 2016-06-14 | 2023-03-06 | Regeneron Pharma | Anti-C5 Antibodies and Uses Thereof |
| MY198182A (en) | 2016-10-12 | 2023-08-09 | Bioverativ Usa Inc | Anti-C1s Antibodies and Methods of use Thereof |
| MX2019008827A (es) | 2017-01-30 | 2019-09-26 | Alexion Pharma Inc | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. |
| JP7209637B2 (ja) * | 2017-04-21 | 2023-01-20 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 自己免疫性水疱症の治療のためのコバーシン |
| CN117327188A (zh) | 2017-07-11 | 2024-01-02 | 亚力兄制药公司 | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 |
| FI3658184T3 (fi) | 2017-07-27 | 2023-11-30 | Alexion Pharma Inc | Korkean pitoisuuden omaavia anti-c5-vasta-aineformulaatioita |
| JP7518764B2 (ja) | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与 |
| KR20200098528A (ko) * | 2017-12-13 | 2020-08-20 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 조합물 및 이의 용도 |
| EP3737750B1 (en) | 2018-01-09 | 2024-06-05 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| US11638699B2 (en) | 2018-03-20 | 2023-05-02 | Theriva Biologics, Inc. | Intestinal alkaline phosphatase formulations |
| WO2019183209A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| WO2019231983A1 (en) | 2018-05-31 | 2019-12-05 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| JP7538723B2 (ja) | 2018-06-28 | 2024-08-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体の産生方法 |
| AU2019370295A1 (en) | 2018-10-30 | 2021-06-03 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| KR20220005560A (ko) | 2019-05-06 | 2022-01-13 | 신세틱 바이오로직스, 인코퍼레이티드 | 알칼리성 포스페이트-기반 종양학 치료제 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| KR20230142831A (ko) | 2021-01-13 | 2023-10-11 | 비스테라, 인크. | 인간화된 보체 5a 수용체 1 항체 및 이의 사용 방법 |
| CN116338208A (zh) * | 2023-03-30 | 2023-06-27 | 石河子大学 | 用于母猪早期妊娠诊断的蛋白生物标志物及其应用 |
| CN117380279B (zh) * | 2023-10-13 | 2025-08-15 | 台州学院 | 一种P-ZIF-8/CaIn2S4复合材料及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| NO162210C (no) * | 1987-07-20 | 1989-11-22 | Fasting Biotech As | Monoklonale antistoffer mot c5a for in-vitro anvendelse ved immunologiske kvantitative teknikker eller ved isolering av c5a. |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| KR100419037B1 (ko) | 1994-03-07 | 2004-06-12 | 넥타르 테라퓨틱스 | 폐를통한인슐린의전달방법및그조성물 |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US7056897B2 (en) | 1997-11-03 | 2006-06-06 | The Arizona Board Of Regents | Inducible expression vectors and methods of use thereof |
| JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| KR20000065395A (ko) * | 1999-04-02 | 2000-11-15 | 김영환 | 단전자 트랜지스터의 제조 방법 |
| WO2000061178A1 (en) | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| EP1169053A1 (en) | 1999-04-13 | 2002-01-09 | Inhale Therapeutic Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| GB9910975D0 (en) | 1999-05-13 | 1999-07-14 | Univ Strathclyde | Rapid dehydration of proteins |
| US6673346B1 (en) | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
| WO2003025020A1 (en) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Method of constructing camel antibody library |
| CN1642983A (zh) * | 2002-01-25 | 2005-07-20 | G2治疗有限公司 | 抗C5aR抗体及其应用 |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US7455837B2 (en) | 2002-11-05 | 2008-11-25 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| US20070065433A1 (en) | 2003-02-21 | 2007-03-22 | Mollnes Tom E | Methods and compositions for the treatment of meconium aspiration syndrome |
| US20070123466A1 (en) | 2003-05-13 | 2007-05-31 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of treating recurrent miscarriages |
| MXPA05011886A (es) | 2003-05-15 | 2006-02-17 | Tanox Inc | Metodos y composiciones para la prevencion y tratamiento de septicemia. |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| GB0416328D0 (en) | 2004-07-21 | 2004-08-25 | Univ Cardiff | Use of dry powder compositions for pulmonary delivery |
| JP2008523083A (ja) * | 2004-12-08 | 2008-07-03 | イムノメディクス， インコーポレイテッド | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
| CA2605024C (en) | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2520588A1 (en) | 2005-08-19 | 2012-11-07 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| RU2445975C2 (ru) * | 2006-03-02 | 2012-03-27 | Алексион Фармасьютикалз, Инк. | Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента |
| US8037880B2 (en) | 2006-04-07 | 2011-10-18 | The University Of Western Ontario | Dry powder inhaler |
| KR20100015773A (ko) * | 2007-03-22 | 2010-02-12 | 노파르티스 아게 | Ｃ５ 항원 및 그의 용도 |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| JP6049163B2 (ja) * | 2008-07-21 | 2016-12-21 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 改善された治療上の特徴のための抗体の構造変異体 |
| WO2010030789A1 (en) * | 2008-09-10 | 2010-03-18 | Novelmed Therapeutics, Inc. | Device and method for inhibiting complement activation |
| CA2742802C (en) * | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| US20110262456A1 (en) * | 2008-11-14 | 2011-10-27 | Rekha Bansal | Method of treating ischemia reperfusion injury |
-
2010
- 2010-06-22 US US12/820,654 patent/US20110002931A1/en not_active Abandoned
- 2010-06-22 EP EP10792563.8A patent/EP2445937B1/en active Active
- 2010-06-22 CN CN2010800373524A patent/CN102597005A/zh active Pending
- 2010-06-22 WO PCT/US2010/039448 patent/WO2010151526A1/en not_active Ceased
- 2010-06-22 JP JP2012517642A patent/JP2012531418A/ja not_active Withdrawn
- 2010-06-22 AU AU2010264520A patent/AU2010264520A1/en not_active Abandoned
- 2010-06-22 CA CA2766565A patent/CA2766565A1/en not_active Abandoned
- 2010-06-22 BR BRPI1012759A patent/BRPI1012759A2/pt not_active IP Right Cessation
- 2010-06-22 RU RU2012102021/10A patent/RU2012102021A/ru unknown
- 2010-06-22 MX MX2011013748A patent/MX2011013748A/es not_active Application Discontinuation
- 2010-06-22 NZ NZ597259A patent/NZ597259A/en not_active IP Right Cessation
- 2010-06-22 KR KR1020127001498A patent/KR20120105405A/ko not_active Withdrawn
-
2011
- 2011-12-19 IL IL217087A patent/IL217087A0/en unknown
-
2012
- 2012-01-16 IN IN424DEN2012 patent/IN2012DN00424A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010151526A1 (en) | 2010-12-29 |
| KR20120105405A (ko) | 2012-09-25 |
| NZ597259A (en) | 2014-04-30 |
| JP2012531418A (ja) | 2012-12-10 |
| EP2445937A4 (en) | 2013-06-19 |
| CA2766565A1 (en) | 2010-12-29 |
| CN102597005A (zh) | 2012-07-18 |
| AU2010264520A1 (en) | 2012-01-19 |
| MX2011013748A (es) | 2012-04-20 |
| RU2012102021A (ru) | 2013-07-27 |
| IL217087A0 (en) | 2012-02-29 |
| EP2445937A1 (en) | 2012-05-02 |
| IN2012DN00424A (pt) | 2015-05-15 |
| EP2445937B1 (en) | 2017-05-24 |
| US20110002931A1 (en) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012759A2 (pt) | anticorpos biespecíficos que se ligam as proteínas do complemento. | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| BR112015012987A2 (pt) | composições compreendendo anticorpos anti-cd38 e lenalidomida | |
| PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
| PH12015500435A1 (en) | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions | |
| BR112017003582A2 (pt) | anticorpos, composições e usos | |
| MX369148B (es) | Agentes de unión kir3dl2. | |
| MX2017001011A (es) | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. | |
| BR112014010532A2 (pt) | anticorpo e métodos para inibição seletiva de respostas de célula-t | |
| MX2015010836A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado. | |
| NZ737418A (en) | Anti-ntb-a antibodies and related compositions and methods | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| PH12015502388A1 (en) | Compositions and methods for altering second messenger signaling | |
| UY36289A (es) | ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN | |
| MX2018002610A (es) | Anticuerpos anti-lag-3. | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| MX2020007021A (es) | Receptor quimerico de antigeno anti-cd19 humanizado. | |
| MX2014000142A (es) | Uso de anticuerpos agonistas anti-cd83 para tratar enfermedades autoinmunes. | |
| MX353476B (es) | Anticuerpos anti-cxcl13 y metodos para usarlos. | |
| MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
| EA201590528A1 (ru) | Антитела к мсам и способы их применения | |
| EA201590247A1 (ru) | Антитела к siglec-15 | |
| BR112016020009A2 (pt) | anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| MX374817B (es) | Miembros de union para il-1 beta. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A, 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2531 DE 09-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |